Audio Journal of Oncology in Advance – January 1st, 2007 – Reporting from San Antonio Breast Cancer Symposium, December 14-17, 2006

Dennis Slamon

George Peoples

James Holland

Massimo Christofanilli

Trastuzumab: Mature Results in Early Breast Cancer Show Superiority

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52
DENNIS SLAMON, University of California, Los Angeles
Adjuvant therapy regimens containing trastuzumab have proved superior to those with cytotoxic chemotherapy agents alone, used without the new molecular therapy. Mature results from the massive BCIRG 006 phase III randomized trial looking at adjuvant doxorubicin, cyclophosphamide, docetaxel with or without trastuzumab were presented in San Antonio by Dennis Slamon, who discussed the details with Peter Goodwin.

HER2 Peptide Vaccine Prevents Breast Cancer Recurrence

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 4
GEORGE PEOPLES, Brook Army Medical Center, Houston
A vaccine to prevent breast cancer has shown early success in a study reported in San Antonio. A group from Houston presented results from the first trial of vaccination against recurrent breast cancer using the E75 single peptide vaccine. George Peoples told Karen Regester how the vaccine improved progression free survival.

Virus Cause of Breast Cancers?

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 6
JAMES HOLLAND, Mount Sinai School of Medicine, New York
A virus may be the cause of human breast cancer, according to James Holland, who gave the San Antonio conference his latest findings implicating human mammary tumor virus as a leading cause of breast cancer. He discussed the data with Peter Goodwin.

Lapatinib Shows Promise as Therapy For Inflammatory Breast Cancer

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 1
MASSIMO CHRISTOFANILLI, MD Anderson Cancer Center, Houston
Targeted therapy may be the best way to combat aggressive inflammatory breast cancer. Massimo Christofanilli and his colleagues selected patients with HER2neu and EGFR expression for therapy with the dual targeted inhibitor, lapatinib. Benefits were apparent within the first two weeks of treatment.

To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.